A phase II study with tegafur/uracil and peg-interferon after TACE [trans-arterial chemoembolisation] for hepatocellular carcinoma

Trial Profile

A phase II study with tegafur/uracil and peg-interferon after TACE [trans-arterial chemoembolisation] for hepatocellular carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Peginterferon (Primary) ; Tegafur/uracil (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 May 2016 Status changed from recruiting to discontinued.
    • 05 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top